Changes in cerebral function parameters in HIV-1 infected subjects undergoing a treatment simplification to darunavir/ritonavir
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-2652
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Changes in cerebral function parameters in HIV-1 infected subjects undergoing a treatment simplification to darunavir/ritonavir ; volume:13 ; number:4 ; day:8 ; month:11 ; year:2010 ; pages:1 ; date:12.2010
Journal of the International AIDS Society / International AIDS Society ; 13, Heft 4 (8.11.2010), 1, 12.2010
- Creator
-
Garvey, LJ
- Contributor
-
Higgs, C.
Mohammed, P.
Nelson, M.
Winston, A.
SpringerLink (Online service)
- DOI
-
10.1186/1758-2652-13-S4-P52
- URN
-
urn:nbn:de:1111-2016052057761
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Garvey, LJ
- Higgs, C.
- Mohammed, P.
- Nelson, M.
- Winston, A.
- SpringerLink (Online service)
Other Objects (12)
Switching to dual therapy with darunavir/ritonavir and etravirine: a simplification strategy
Hepatic tolerability of fosamprenavir/ritonavir (FPV/RTV) in HIV/hepatitis C co-infected subjects with severe hepatic fibrosis
Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1
Simplification
The effect of food on ritonavir bioavailability following administration of ritonavir 100 mg film-coated tablet in healthy adult subjects
A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients
Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d’Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial
Randomization and Simplification
Population pharmacokinetic/pharmacodynamic analysis of lopinavir and ritonavir in subjects receiving the tablet formulation
Switching to dual therapy with darunavir/ritonavir and etravirine: a simplification strategy
Hepatic tolerability of fosamprenavir/ritonavir (FPV/RTV) in HIV/hepatitis C co-infected subjects with severe hepatic fibrosis
Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1
Simplification
The effect of food on ritonavir bioavailability following administration of ritonavir 100 mg film-coated tablet in healthy adult subjects
A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients
Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d’Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial
Randomization and Simplification
Population pharmacokinetic/pharmacodynamic analysis of lopinavir and ritonavir in subjects receiving the tablet formulation
Switching to dual therapy with darunavir/ritonavir and etravirine: a simplification strategy
Hepatic tolerability of fosamprenavir/ritonavir (FPV/RTV) in HIV/hepatitis C co-infected subjects with severe hepatic fibrosis
Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1
Simplification
The effect of food on ritonavir bioavailability following administration of ritonavir 100 mg film-coated tablet in healthy adult subjects
A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
Herb-drug interaction between Echinacea purpurea and darunavir/ritonavir in HIV-infected patients
Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d’Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial
Randomization and Simplification